These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6140695)

  • 41. Auditory evoked potentials as possible predictors of outcome in schizophrenic outpatients.
    Hegerl U; Gaebel W; Gutzman H; Ulrich G
    Int J Psychophysiol; 1988 Aug; 6(3):207-14. PubMed ID: 2900230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Perazine therapy. Seminar, Hamburg, 12-14 November 1992].
    Nervenarzt; 1993 Jan; 64(1 Suppl):1-8. PubMed ID: 7477594
    [No Abstract]   [Full Text] [Related]  

  • 43. [Experiences of schizophrenic patients in ambulatory care with oral neuroleptics--baseline for psychoeducational interventions].
    Hornung WP; Franzen U; Buchkremer G
    Schweiz Arch Neurol Psychiatr (1985); 1994; 145(4):18-22. PubMed ID: 7534435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenics.
    Cutler NR; Jeste DV; Kaufmann CA; Karoum F; Schran HF; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):277-83. PubMed ID: 6146164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants.
    Daniel WA; Wójcikowski J
    Eur Neuropsychopharmacol; 1999 Dec; 9(6):483-91. PubMed ID: 10625116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated clozapine serum levels in combination with perazine.
    Fischer M; Unterecker S; Deckert J; Pfuhlmann B
    Psychopharmacology (Berl); 2013 Apr; 226(3):623-5. PubMed ID: 23397051
    [No Abstract]   [Full Text] [Related]  

  • 47. An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study.
    Kolakowska T; Gadhvi H; Molyneux S
    Int Clin Psychopharmacol; 1987 Jan; 2(1):83-8. PubMed ID: 2889761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A case of perazine-induced enteritis--allergy or pseudoallergy?
    Meya U; Möller B; Renfordt E; Lobeck H
    Pharmacopsychiatry; 1985 Jul; 18(4):263-6. PubMed ID: 2862649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determination of perazine serum levels by gas liquid chromatography under clinical routine conditions.
    Schley J; Riedel E; Müller-Oerlinghausen B
    J Clin Chem Clin Biochem; 1978 May; 16(5):307-11. PubMed ID: 27569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antipsychotic effect of propranolol on chronic schizophrenics: study of a gradual treatment regimen.
    Elizur A; Segal Z; Yeret A; Davidson S; Atsmon A
    Psychopharmacology (Berl); 1979 Jan; 60(2):189-94. PubMed ID: 34185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gas-liquid chromotographic determination of perazine, thioridazine and thioridazine metabolites in human plasma.
    Vanderheeren FA; Theunis DJ
    J Chromatogr; 1976 May; 120(1):123-8. PubMed ID: 5459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reliable routine method for determination of perazine in serum by thin-layer chromatography with an internal standard.
    Kresse M; Schley J; Müller-Oerlinghausen B
    J Chromatogr; 1980 Oct; 183(4):475-82. PubMed ID: 6107303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Determination of the binding of perazine and perazine sulfoxide to human serum albumin].
    Kinawi A; Lüth B; Mohamed-Ali H
    Arch Pharm (Weinheim); 1980 May; 313(5):443-8. PubMed ID: 6105858
    [No Abstract]   [Full Text] [Related]  

  • 54. Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals.
    Brinkschulte M; Breyer-Pfaff U
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Jul; 308(1):1-7. PubMed ID: 40137
    [No Abstract]   [Full Text] [Related]  

  • 55. High affinity binding of perazine and desmethylperazine to human alpha 1-acid glycoprotein.
    Schley J; Nündel M; Siegert M; Riedel E; Müller-Oerlinghausen B
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):144-5. PubMed ID: 6104826
    [No Abstract]   [Full Text] [Related]  

  • 56. [Expanding therapeutic reference ranges using dose-related reference ranges].
    Haen E; Greiner C; Bader W; Wittmann M
    Nervenarzt; 2008 May; 79(5):558-66. PubMed ID: 18414826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 beta levels in the rat brain.
    Obuchowicz E; Marcinowska A; Drzyzga L; Wójcikowski J; Daniel WA; Herman ZS
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Apr; 373(1):79-84. PubMed ID: 16583240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-dose kinetics of the neuroleptic drug perazine in psychotic patients.
    Breyer-Pfaff U; Nill K; Schied HW; Gaertner HJ; Giedke H
    Psychopharmacology (Berl); 1988; 95(3):374-7. PubMed ID: 2901127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
    Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
    Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.